{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:57:39Z","timestamp":1760385459253},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T00:00:00Z","timestamp":1453680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0147821","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T19:11:15Z","timestamp":1453749075000},"page":"e0147821","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States"],"prefix":"10.1371","volume":"11","author":[{"given":"Donna","family":"E. Sweet","sequence":"first","affiliation":[]},{"given":"Frederick","family":"L. Altice","sequence":"additional","affiliation":[]},{"given":"Calvin","family":"J. Cohen","sequence":"additional","affiliation":[]},{"given":"Bj\u00f6rn","family":"Vandewalle","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2016,1,25]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"MA Thompson","year":"2012","journal-title":"JAMA"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada","volume":"8","author":"H Samji","year":"2013","journal-title":"PLoS ONE"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7326\/0003-4819-146-2-200701160-00003","article-title":"Survival of persons with and without HIV infection in Denmark, 1995\u20132005","volume":"146","author":"N Lohse","year":"2007","journal-title":"Ann Intern Med"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"e31591","DOI":"10.1371\/journal.pone.0031591","article-title":"Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States","volume":"7","author":"PE Sax","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/QAD.0b013e32834dce6e","article-title":"Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults","volume":"26","author":"CE Sloan","year":"2012","journal-title":"AIDS"},{"key":"ref6","first-page":"193","article-title":"New strategies for lowering the costs of antiretroviral treatment and care for people with HIV\/AIDS in the United Kingdom","volume":"4","author":"B Gazzard","year":"2012","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-158-2-201301150-00002","article-title":"Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States","volume":"158","author":"RP Walensky","year":"2013","journal-title":"Ann Intern Med"},{"issue":"17","key":"ref8","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1097\/QAD.0b013e32833f3c14","article-title":"Contemporary costs of HIV healthcare in the HAART era","volume":"24","author":"KA Gebo","year":"2010","journal-title":"AIDS"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/01.mlr.0000228021.89490.2a","article-title":"The lifetime cost of current human immunodeficiency virus care in the United States","volume":"44","author":"BR Schackman","year":"2006","journal-title":"Med Care"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"e98152","DOI":"10.1371\/journal.pone.0098152","article-title":"Cost of treatment in a US commercially insured, HIV-1-infected population","volume":"9","author":"CT Solem","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"e97482","DOI":"10.1371\/journal.pone.0097482","article-title":"Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks&apos; follow-up","volume":"9","author":"FJ Lee","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003028","article-title":"Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV","volume":"3","author":"CJ Cohen","year":"2013","journal-title":"BMJ Open"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10640-005-6030-6","article-title":"The Willingness to Accept Value of Statistical Life Relative to the Willingness to Pay Value: Evidence and Policy Implications","volume":"32","author":"J Guria","year":"2005","journal-title":"Environmental & Resource Economics"},{"key":"ref14","unstructured":"Gilead. Market share data, quarter 4. 2013."},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jama.296.12.1498","article-title":"Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection","volume":"296","author":"B Rodriguez","year":"2006","journal-title":"JAMA"},{"key":"ref16","unstructured":"FDA. Emtricitabine\/rilpivirine\/tenofovir disoproxil fumarate full prescribing information. 2011."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Sweet D, Kim Y, Zhong Y, Zhuo D, Signorovitch J. Real-World Adherence among Patients Receiving Single versus Multiple Tablet Regimens for HIV-1 Infection, and Associations between Adherence and Viral Suppression: A Systematic Literature Review and Meta- Analysis. 20th International AIDS Conference Melbourne, Australia, 2014; 2014.","DOI":"10.7448\/IAS.17.4.19537"},{"issue":"9835","key":"ref18","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"PE Sax","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/QAI.0000000000000057","article-title":"A randomized, double-blind comparison of single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus single-tablet regimen efavirenz\/emtricitabine\/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results","volume":"65","author":"DA Wohl","year":"2014","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0b013e318289545c","article-title":"A randomized double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results","volume":"63","author":"A Zolopa","year":"2013","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults","volume":"28","author":"C Cohen","year":"2014","journal-title":"AIDS"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/QAI.0000000000000017","article-title":"Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine\/emtricitabine\/tenofovir DF or efavirenz\/emtricitabine\/tenofovir DF in the STaR study (GS-US-264-0110)","volume":"65","author":"DP Porter","year":"2014","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1310\/hct0803-164","article-title":"The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients","volume":"8","author":"I Cassetti","year":"2007","journal-title":"HIV clinical trials"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"JE Gallant","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00002030-200501280-00007","article-title":"Atazanavir plus ritonavir or saquinavir, and lopinavir\/ritonavir in patients experiencing multiple virological failures","volume":"19","author":"M Johnson","year":"2005","journal-title":"AIDS"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.aids.0000216371.76689.63","article-title":"96-week comparison of once-daily atazanavir\/ritonavir and twice-daily lopinavir\/ritonavir in patients with multiple virologic failures","volume":"20","author":"M Johnson","year":"2006","journal-title":"AIDS"},{"issue":"9568","key":"ref27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"B Clotet","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","article-title":"Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1","volume":"21","author":"C Katlama","year":"2007","journal-title":"AIDS"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/QAD.0b013e3280b07b47","article-title":"Week 24 efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients","volume":"21","author":"R Haubrich","year":"2007","journal-title":"AIDS"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3851\/IMP1301","article-title":"Efficacy and safety of darunavir\/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96","volume":"14","author":"K Arasteh","year":"2009","journal-title":"Antiviral therapy"},{"key":"ref31","unstructured":"Janssen. POWER 1 and 2: 96-Week Pooled Analysis 2015 [19 March 2015]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.prezista.com\/healthcare\/claims\/power-study\" xlink:type=\"simple\">http:\/\/www.prezista.com\/healthcare\/claims\/power-study<\/ext-link>."},{"issue":"9893","key":"ref32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"P Cahn","year":"2013","journal-title":"Lancet"},{"key":"ref33","unstructured":"Pozniak A, Mingrone H, Shuldyakov A, Brites C, Federico Andrade-Villanueva J, Hagins D, et al. editors. Dolutegravir (DTG) Versus Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: 24-Week Interim Results From SAILING (ING111762) 20th Conference on Retroviruses and Opportunistic Infections; 2013; Atlanta, GA"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"A Castagna","year":"2014","journal-title":"J Infect Dis"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/01.qai.0000185314.56556.c3","article-title":"Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials","volume":"40","author":"M Nelson","year":"2005","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.qai.0000185313.48933.2c","article-title":"Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks","volume":"40","author":"B Trottier","year":"2005","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"564","DOI":"10.7326\/0003-4819-146-8-200704170-00007","article-title":"Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes","volume":"146","author":"JB Nachega","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"ref38","article-title":"United States Life Tables, 2010","volume":"63","year":"2014","journal-title":"National Vital Statistics Reports"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00126334-200002010-00009","article-title":"Course of viral load throughout HIV-1 infection","volume":"23","author":"CA Sabin","year":"2000","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/088922299311024","article-title":"Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial","volume":"15","author":"J Cook","year":"1999","journal-title":"AIDS research and human retroviruses"},{"key":"ref41","unstructured":"Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers (CPI-U): U. S. city average, by expenditure category 2015 [cited 2015]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.bls.gov\/news.release\/cpi.t01.htm\" xlink:type=\"simple\">http:\/\/www.bls.gov\/news.release\/cpi.t01.htm<\/ext-link>."},{"issue":"1","key":"ref42","first-page":"41","article-title":"The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients","volume":"13","author":"AM Hill","year":"2011","journal-title":"AIDS reviews"},{"key":"ref43","article-title":"Impact of HAART Regimen on Adherence and Risk of Hospitalization in HIV\/AIDS Patients Using VA Data ICAAC","author":"G Rao","year":"2013"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1524-4733.2008.00326.x","article-title":"A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy","volume":"11","author":"TL Kauf","year":"2008","journal-title":"Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"issue":"9","key":"ref45","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"PJ Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"e113031","DOI":"10.1371\/journal.pone.0113031","article-title":"HIV cure strategies: how good must they be to improve on current antiretroviral therapy?","volume":"9","author":"PE Sax","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"ref47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/MLR.0000000000000308","article-title":"The lifetime medical cost savings from preventing HIV in the United States","volume":"53","author":"BR Schackman","year":"2015","journal-title":"Med Care"},{"key":"ref48","unstructured":"DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2015."},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328335cd8a","article-title":"Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial","volume":"24","author":"EM Gardner","year":"2010","journal-title":"AIDS"},{"issue":"Suppl 2","key":"ref50","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/jit107","article-title":"Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings","volume":"207","author":"MC Hosseinipour","year":"2013","journal-title":"The Journal of infectious diseases"},{"issue":"10\u201311","key":"ref51","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.ress.2005.11.025","article-title":"Bayesian analysis of computer code outputs: A tutorial","volume":"91","author":"A O\u2019Hagan","year":"2006","journal-title":"Reliability Engineering & System Safety"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/CEOR.S24130","article-title":"Cost-effectiveness analysis of initial HIV treatment under Italian guidelines","volume":"3","author":"GL Colombo","year":"2011","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/CEOR.S38977","article-title":"Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen","volume":"5","author":"GL Colombo","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref54","first-page":"53","article-title":"Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation","volume":"6","author":"F Maggiolo","year":"2015","journal-title":"Patient related outcome measures"},{"key":"ref55","unstructured":"WHO. Pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature. 2012."},{"key":"ref56","first-page":"9","article-title":"Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting","volume":"10","author":"GL Colombo","year":"2014","journal-title":"Therapeutics and clinical risk management"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/379667","article-title":"Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients","volume":"188","author":"FS Rousseau","year":"2003","journal-title":"The Journal of infectious diseases"},{"issue":"9","key":"ref58","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials","volume":"58","author":"JB Nachega","year":"2014","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"9","key":"ref59","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/MLR.0b013e31821b34c0","article-title":"Determinants of the cost of health services used by veterans with HIV","volume":"49","author":"PG Barnett","year":"2011","journal-title":"Med Care"},{"issue":"9","key":"ref60","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.eimc.2013.06.008","article-title":"Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reduction","volume":"32","author":"MA Ramiro","year":"2014","journal-title":"Enfermedades infecciosas y microbiologia clinica"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0147821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T10:38:04Z","timestamp":1600079884000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0147821"}},"subtitle":[],"editor":[{"given":"Viviane D.","family":"Lima","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2016,1,25]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0147821","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,25]]}}}